Placebo for Lebrikizumab

DRUG2 trials

Sponsors

Eli Lilly & Co.

Conditions

Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)Perennial Allergic Rhinitis (PAR)

Phase 3

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lebrikizumab/LY3650150 in Participants with Chronic Rhinosinusitis with Nasal Polyps on Background Intranasal Corticosteroids

RecruitingCTIS2023-508760-29-00

Eli Lilly & Co.Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

Start: 2024-10-21Target: 231Updated: 2025-09-22

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lebrikizumab/ LY3650150 in Adult Participants With Perennial Allergic Rhinitis

RecruitingCTIS2023-508817-18-00

Eli Lilly & Co.Perennial Allergic Rhinitis (PAR)

Start: 2024-10-08Target: 258Updated: 2025-10-20